Cleveland BioLabs is a clinical-stage biotech developing a robust pipeline of drugs for multiple medical and defense applications.
Cleveland BioLabs is a clinical-stage biotech developing a robust pipeline of drugs for multiple medical and defense applications, with a focus on oncology and tissue protection. The company pursues the research, development, and commercialization of proprietary products that have the potential to treat cancer, prevent, and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients.Cleveland BioLabs was established in 2003 and is headquartered in Buffalo, New York.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 1, 2013 | Post-IPO Debt | $10M | 1 | Hercules Capital | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Hercules Capital | Yes | Post-IPO Debt |